ARTICLE | Distillery Therapeutics
Autoimmune disease
November 13, 2018 6:49 PM UTC
Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity compared with normal MCP-1 expression or an isotype control antibody. Next steps could include identifying and testing MCP-1 and CCR2 inhibitors in models of arthritis.
Noxxon Pharma N.V. has emapticap pegol, an L-aptamer MCP-1 inhibitor, in Phase I/II testing for solid tumors...
BCIQ Company Profiles